Levofloxacin Induced Stomatitis: A Case Report Hakamifard, Atousa; Mousavi, Sarah; Gholipur-Shahraki, Tahereh ...
Journal of pharmaceutical care,
10/2019, Letnik:
7, Številka:
1-2
Journal Article
Odprti dostop
Fluoroquinolones have many adverse effects include the gastrointestinal tract and the central nervous system, phototoxicity, and dermal toxicity. Levofloxacin has favorable adverse reaction profiles ...compared to other fluoroquinolones. Among the reported dermal toxicity there are few reports of toxic epidermal necrosis (TEN) in association with levofloxacin usage. However, there is no published study on levofloxacin induced stomatitis. Stomatitis is characterized by pain, inflammation, and ulceration in the oral cavity. A 36-year-old man was referred to the hospital for ‘painful oral swelling and ulceration’. Before the admission due to fever and productive cough, 750 mg levofloxacin were prescribed for him. After 2 days of consumption, the patient experiences painful ulcerative and erythema lesions in the oral cavity that consistent with stomatitis. Due to the possibility of a drug reaction, levofloxacin was discontinued and no other antibiotic was used. Oral lesions were managed with a mouthwash and after 5 days, lesions recovered. To the best of our knowledge, this is the first case who developed stomatitis after two dose of levofloxacin and recovered just with topical therapy and without any systemic treatment. Caution is advised while administering these drugs.
Rituximab associated necrosis: A case report Ashtari, Fereshteh; Hakamifard, Atousa; Hariri, Amirali ...
Multiple sclerosis and related disorders,
January 2020, 2020-Jan, 2020-01-00, Letnik:
37
Journal Article
•Rituximab has been frequently utilized for the treatment of a wide range of neurologic diseases including 'Devic's syndrome.•Previous case reports have described cases of osteonecrosis, retinal and ...nasal skin necrosis.•This case report addresses a patient with 'Devic's syndrome presented with palatal mucosal necrosis after rituximab treatment.•Due to the increasing administration of rituximab, awareness about mucosal necrosis should be raised.
Rituximab is a B-cell-depleting unconjugated monoclonal IgG1 antibody that targets the transmembrane protein CD20. This article reports on a case with the rare complication known as Rituximab-associated mucosal necrosis.
The present case report addresses, for the first time, a patient affected by Devic's syndrome presenting with oral manifestations of palatal necrosis after rituximab treatment.
The present case raises the possibility of anti-CD20 antibody contributing to the development of palatal mucosal necrosis in some patients. Given the increasing administration of rituximab as a result of its efficacy against several diseases, a report on the potential iatrogenic effects of this drug is essential.
Megaloblastic anemia is a common disorder with various manifestations. Of the many causes, cobalamin or folate deficiency can eventuate into megaloblastic anemia. It can lead to pancytopenia and mild ...to moderate splenomegaly, but massive splenomegaly rarely seen in this situation. We describe a 39-yearold woman with marked enlargement of the spleen and pancytopenia that was found to have megaloblastic anemia. The splenomegaly and blood count resolved 4 months after initiation of vitamin B12 therapy. It is important to know massive splenomegaly may occur in megaloblastic anemia, and although it is rare, bur can reversible with early treatment.
BACKGROUNDRituximab is a B-cell-depleting unconjugated monoclonal IgG1 antibody that targets the transmembrane protein CD20. This article reports on a case with the rare complication known as ...Rituximab-associated mucosal necrosis. CASE PRESENTATIONThe present case report addresses, for the first time, a patient affected by Devic's syndrome presenting with oral manifestations of palatal necrosis after rituximab treatment. CONCLUSIONThe present case raises the possibility of anti-CD20 antibody contributing to the development of palatal mucosal necrosis in some patients. Given the increasing administration of rituximab as a result of its efficacy against several diseases, a report on the potential iatrogenic effects of this drug is essential.
PDF
